S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:ONVO

Organovo Stock Forecast, Price & News

$10.68
-0.71 (-6.23 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.34
Now: $10.68
$11.84
50-Day Range
$11.30
MA: $14.67
$21.70
52-Week Range
$3.87
Now: $10.68
$23.92
Volume351,315 shs
Average Volume455,102 shs
Market Capitalization$76.01 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.
Organovo logo

Headlines

Organovo Holdings Inc.
January 29, 2021 |  barrons.com
ARKG: Don't Always Follow The Leader - Seeking Alpha
January 6, 2021 |  seekingalpha.com
78 Biggest Movers From Friday - Benzinga
December 21, 2020 |  benzinga.com
Organovo Holdings Inc
October 23, 2020 |  bloomberg.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000
Employees7
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.20 million
Book Value$4.08 per share

Profitability

Net Income$-18,710,000.00

Miscellaneous

Market Cap$76.01 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.67 out of 5 stars

Medical Sector

1262nd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

147th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$10.68
-0.71 (-6.23 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Organovo (NASDAQ:ONVO) Frequently Asked Questions

What stocks does MarketBeat like better than Organovo?

Wall Street analysts have given Organovo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Organovo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Organovo?

Organovo saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 268,100 shares, a decline of 23.6% from the January 28th total of 351,000 shares. Based on an average trading volume of 385,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.8% of the company's stock are short sold.
View Organovo's Short Interest
.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Organovo
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) released its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million.
View Organovo's earnings history
.

How has Organovo's stock been impacted by COVID-19?

Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONVO shares have increased by 105.4% and is now trading at $10.68.
View which stocks have been most impacted by COVID-19
.

When did Organovo's stock split? How did Organovo's stock split work?

Organovo's stock reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

Who are Organovo's key executives?

Organovo's management team includes the following people:
  • Mr. Keith E. Murphy, Exec. Chairman & Principal Exec. Officer (Age 49, Pay $1.39M)
  • Mr. Chris Heberlig CPA, M.B.A., Pres & CFO (Age 46)
  • Dr. Jeffrey N. Miner, Chief Scientific Officer
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
  • Mr. Thomas Einar Jurgensen, Gen. Counsel

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.36%), Jane Street Group LLC (0.23%) and Northern Trust Corp (0.22%).
View institutional ownership trends for Organovo
.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Organovo
or view top insider-selling stocks.

Which major investors are buying Organovo stock?

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Northern Trust Corp.
View insider buying and selling activity for Organovo
or or view top insider-buying stocks.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $10.68.

How much money does Organovo make?

Organovo has a market capitalization of $76.01 million and generates $2.20 million in revenue each year.

How many employees does Organovo have?

Organovo employs 7 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

Where are Organovo's headquarters?

Organovo is headquartered at 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.